Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 26 of 26 results for cetuximab

  1. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: 11 June 2025

    Technology appraisal guidance
    In development

  2. Past appeals and decisions

    January 2014 TA118 Colorectal cancer (metastatic) - bevacizumab & cetuximab 27 November 2006 TA102 Conduct disorder in children -...

  3. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA212

  4. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued [GID-TAG395]

    Technology appraisal guidance
    Discontinued

  5. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the

    Diagnostics guidance
    Published
    10 December 2014
    View recommendations

    Sections for DG16

  6. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued [GID-DT14]

    Diagnostics guidance
    Discontinued

  7. Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

    This guidance has been updated and replaced by NICE technology appraisal guidance 439.

    Technology appraisal guidance
    Published
    26 August 2009

  8. Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy (TA150)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 242.

    Technology appraisal guidance
    Published
    25 June 2008

  9. Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (TA172)

    This guidance has been updated and replaced by NICE technology appraisal guidance 473.

    Technology appraisal guidance
    Published
    24 June 2009

  10. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    25 March 2014
    View recommendations

    Sections for TA307

  11. Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)

    Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy

    Diagnostics guidance
    Published
    10 May 2017

    Sections for DG28